Covid Drug: New oral antiviral drug likely to get Centre’s approval for treating Covid, Health News, ET HealthWorld

Pune: The Union health ministry is likely to include an oral antiviral drug, nirmatrelvir-ritonavir combination, in the country’s upcoming Covid treatment protocol for patients with mild to moderate disease, who are at high risk of developing severe illness. The combination drug, popularly known by the brand name paxlovid, is currently in high demand in China and a few other nations battling the Covid surge. India’s upcoming Covid treatment protocol is expected to be released within a week. “The combination two-tablet oral drug therapy is likely to be recommended in India…

Read More

Japan’s Fujifilm stops work on Avigan as COVID drug – ET HealthWorld

Tokyo: Fujifilm Holdings Corp has ended the development of its anti-influenza drug Avigan to treat COVID-19, the firm said on Friday, after more than two years of work on a pill once hailed as Japan’s biggest contribution to the global coronavirus fight. In March, Fujifilm had cut short enrolment in a Phase III trial, saying the emergence of the Omicron variant made it tough to measure the drug’s effectiveness in preventing severe symptoms. Subsequent analysis of data from 84 people enrolled in the trial showed no significant results, the company…

Read More

Phase III trials of COVID drug Movfor show positive results, says Hetero – ET HealthWorld

Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine. The results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12-16, 2022, demonstrated that Molnupiravir along with standard of care (SOC) reduced the risk of hospitalisation by over 65 per cent compared to SOC alone. Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug, the Hyderabad-based drug maker said in…

Read More

GSK to increase Covid drug capacity, but no plans for India yet – ET HealthWorld

British drugmaker GSK said it is actively working to expand supply of its Covid-19 monoclonal antibody medication Sotrovimab, to make it available to more patients. “We remain committed to partnering with governments around the world to provide Sotrovimab as a tool in response to the ongoing pandemic,” GSK India spokesperson told ET in a statement. “This includes active work to expand our supply capacity so that we can support more patients over time,” the spokesperson added. The company didn’t specify any timelines on when the drug will be available in…

Read More

Pfizer may offer Covid antiviral drug to India at lower price for now – ET HealthWorld

Pfizer may offer its Covid antiviral drug Paxlovid at lower prices for low and middle income countries (LMICs), including India, as an interim measure as the cheaper generic versions may not be available until later this year. The company on Wednesday said it is in discussions with several nations, including India, to introduce Paxlovid. Pfizer has entered into advance purchase agreements with multiple countries. Sources told ET that Pfizer is yet to apply for emergency use authorisation in India. The country is seeing a surge in Covid cases fuelled by…

Read More

First batch of DRDO’s anti-Covid drug to be released on Monday – ET HealthWorld

The first batch of anti-Covid drug 2-DG, developed by the DRDO, will be released on Monday by defence minister Rajnath Singh and health minister Harsh Vardhan, officials said. The Drugs Controller General of India (DGCI) has approved the oral drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients, the defence ministry said earlier this month. The officials said the first batch of the drug will be released by the two ministers at an event at the headquarters of the Defence Research and Development Organisation (DRDO).…

Read More